NICE issued final draft guidance recommending axicabtagene ciloleucel treatment

Thursday, 26 January: NICE has today  issued final draft guidance recommending the axicabtagene ciloleucel treatment be made routinely available on the NHS for suitable patients. 

Publication of the final guidance is expected on 28 February 2023.

The full draft guidance on axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after two or more systemic therapies is available on the NICE website.